Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer

European Journal of Cardio-thoracic Surgery

Volumn 23, Issue 2, 2003, Pages 221-228

  Cheng, Yeung Leung ^a,b   Lee, Shih Chun ^a   Harn, Horng Jyh ^c   Chen, Cheng Jueng ^a   Chang, Yue Cune ^d   Chen, Jen Chih ^a   Yu, Cheng Ping ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d TAMKANG UNIVERSITY   (Taiwan)

Author keywords

Immonohistochemical analysis; Non small cell lung cancer; p16; p53; Prognosis

Indexed keywords

MONOCLONAL ANTIBODY; PARAFFIN; PROTEIN P16; PROTEIN P53;

ADULT; ADVANCED CANCER; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TISSUE SECTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037307872     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(02)00749-2     Document Type: Article

References (25)

1. Junker K. Prognostic factors in stage I/II non-small cell lung cancer. Lung Cancer. 33:(Suppl. 1):2001;S17-S24.
2. Mountain C.F. Revisions in the international system for staging lung cancer. Chest. 111:1997;1710-1717.
3. Niklinski J., Niklinska W., Laudanski J., Chyczewska E., Chyczewski L. Prognostic molecular markers in non-small cell lung cancer. Lung Cancer. 34:(Suppl. 2):2001;S53-S58.
4. Schneider P.M., Praeuer H.W., Stoeltzing O., Boehm J., Manning J., Metzger R., Fink U., Wegerer S., Hoelscher A.H., Roth J.A. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer. 83:2000;473-479.
5. Sozzi G. Molecular biology of lung cancer. Eur J Cancer. 37:(Suppl. 7):2001;S63-S73.
6. Greatens T.M., Niehans G.A., Rubins J.B., Jessurun J., Kratzke R.A., Maddaus M.A., Niewoehner D.E. Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med. 157:1998;1093-1097.
7. Rosell R., Taron M., O'Brate A. Predictive molecular markers in non-small cell lung cancer. Curr Opin Oncol. 13:2001;101-109.
8. Han H., Landreneau R.J., Santucci T.S., Tung M.Y., Macherey R.S., Shackney S.E., Sturgis C.D., Raab S.S., Silverman J.F. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol. 33:2002;105-110.
9. Kim Y.C., Park K.O., Kern J.A., Park C.S., Lim S.C., Jang A.S., Yang J.B. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer. 22:1998;181-190.
10. Osaki T., Oyama T., Inoue M., Gu C.D., Kodate M., Aikawa M., So T., Mizukami M., Mitsudomi T., Yasumoto K. Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. Prognostic implications. Jpn J Thorac Cardiovasc Surg. 49:2001;545-551.
11. Vogt U., Zaczek A., Klinke F., Granetzny A., Bielawski K., Falkiewicz B. p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer. J Cancer Res Clin Oncol. 128:2002;141-147.
12. Takahashi T., Nau M.M., Chiba I., Birrer M.J., Rosenberg R.K., Vinocour M., Levitt M., Pass H., Gazdar A.F., Minna J.D. p53: a frequent target for genetic abnormalities in lung cancer. Science. 246:1989;491-494.
13. Vogelstein B., Kinzler K.W. p53 function and dysfunction. Cell. 70:1992;523-526.
14. Polyak K., Waldman T., He T.C., Kinzler K.W., Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 10:1996;1945-1952.
15. Hatakeyama M., Weinberg R.A. The role of RB in cell cycle control. Prog Cell Cycle Res. 1:1995;9-19.
16. Gazzeri S., Gouyer V., Vour'ch C., Brambilla C., Brambilla E. Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene. 16:1998;497-504.
17. Lopez-Encuentra A., Bulzebruck H., Feinstein A.R., Motta G., Mountain C.F., Naruke T., Sanchez J.M., Tsuchiya R., Wittekind C. Tumor staging and classification in lung cancer. Summary of the international symposium. Madrid, Spain, 3-4 December 1999. Lung Cancer. 29:2000;79-83.
18. Harn H.J., Hsieh H.F., Ho L.I., Yu C.P., Chen J.H., Chiu C.C., Fan H.C., Lee W.H. Apoptosis in nasopharyngeal carcinoma as related to histopathological characteristics and clinical stage. Histopathology. 33:1998;117-122.
19. Huang C.I., Taki T., Higashiyama M., Kohno N., Miyake M. p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung. Br J Cancer. 82:2000;374-380.
20. Lee J.S., Yoon A., Kalapurakal S.K., Ro J.Y., Lee J.J., Tu N., Hittelman W.N., Hong W.K. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol. 13:1995;1893-1903.
21. Soussi T., Legros Y., Lubin R., Ory K., Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer. 57:1994;1-9.
22. Quinlan D.C., Davidson A.G., Summers C.L., Warden H.E., Doshi H.M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 52:1992;4828-4831.
23. Huncharek M., Kupelnick B., Geschwind J.F., Caubet J.F. Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer Lett. 153:2000;219-226.
24. Geradts J., Fong K.M., Zimmerman P.V., Maynard R., Minna J.D. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res. 5:1999;791-800.
25. Brambilla E., Moro D., Gazzeri S., Brambilla C. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol. 188:1999;351-360.